News
Pharmaceutical Technology on MSN1d
EC approves AstraZeneca’s Imfinzi combo for NSCLCThe European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...
An isogenic cell line was created to model cancer ... ALK. We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung ...
Zacks Investment Research on MSN1d
AZN Gets EU Nod for Expanded Use of Two Separate Cancer DrugsAstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...
Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...
Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback